Primary nephrotic syndrome in children. Prospects for personalized therapy
S.L. MOROZOV, M.E. AKSENOVA
Veltischev Research and Clinical Institute for Pediatrics of the Pirogov Russian National Research Medical University, 2 Taldomskaya Str., Moscow, Russian Federation, 125412
Morozov S.L. – PhD (medicine), Senior Research Associate of the Department of Hereditary and Acquired Kidney Diseases, tel. (495) 483-21-92, e-mail: mser@list.ru
Aksenova M.E. – PhD (medicine), Leading Research Associate of the Department of Hereditary and Acquired Kidney Diseases, tel. (495) 483-21-92, e-mail: marina_aksenova_69@mail.ru
Despite the clinical importance of the use of steroid and immunosuppressive drugs in the treatment of nephrotic syndrome, in most cases the molecular basis of ineffectiveness of immunosuppressive drugs is unknown, and it justifies the need to study the pharmacogenetic aspects of the use of immunosuppressive drugs. The article presents modern data ragading the effect of pharamcogenomics on the pharmacokinetics of steroid and immunosuppressive drugs used in the therapy of nephrotic syndrome, as well as the possibility of genotyping before treatment.
Key words: children, primary nephrotic syndrome, kidneys, personalized therapy, genetic polymorphism, tacrolimus, cyclosporine, prednisolone.
(For citation: Morozov S.L., Aksenova M.E. Primary nephrotic syndrome in children. Prospects for personalized therapy. Practical Medicine. 2018)
REFERENCES
- Samuel N Uwaezuoke. The role of novel biomarkers in childhood idiopathic nephrotic syndrome: a narrative review of published evidence. Int J Nephrol Renovasc, 2017, no. 10, pp. 123-128.
- Dossier C., Lapidus N., Bayer F. et al. Epidemiology of idiopathic nephrotic syndrome in children: endemic or epidemic? Pediatr Nephrol., 2016, no. 31, pp. 2299-2308.
- McKinney P.A., Feltbower R.G., Brocklebank J.T., Fitzpatrick M. M. Time trends and ethnic patterns of childhood nephrotic syndrome in Yorkshire, UK. Pediatric Nephrology, 2001, vol.16, no. 6, pp. 1040–1044.
- Lieberman K.V., Pavlova-Wolf A. Adrenocorticotropic hormone therapy for the treatment of idiopathic nephrotic syndrome in children and young adults: a systematic review of early clinical studies with contemporary relevance. Journal of nephrology, 2016, no. 16, pp. 1-10.
- Selewski D.T., Troost J.P., Cummings D., Massengill S.F. et al. Responsiveness of the PROMIS® measures to changes in disease status among pediatric nephrotic syndrome patients: a Midwest pediatric nephrology consortium study. Health Qual Life Outcomes, 2017, no. 15, p. 166.
- Gipson D.S., Massengill S.F., Yao L. et al. Management of childhood onset nephrotic syndrome. Pediatrics, 2009, no. 124, pp. 747-57.
- Banaszak B., Banaszak P. The increasing incidence of initial steroid resistance in childhood nephrotic syndrome. Pediatr. Nephrol., 2012, no. 27, pp. 927-932.
- Zagury A., Oliveira A.L., Montalvão J.A. et al. Steroid-resistant idiopathic nephrotic syndrome in children: long-term follow up and risk factors for end-stage renal disease. J Bras Nefrol., 2013, vol. 35, no. 3, pp. 191–199.
- Beins N.T., Dell K.M. Long-Term Outcomes in Children with Steroid-Resistant Nephrotic Syndrome Treated with Calcineurin Inhibitors. Front. Pediatr, 2015, no. 3, p. 104.
- Abeyagunawardena A.S., Sebire N.J., Risdon R.A., et al. Predictors of long-term outcome of children with idiopathic focal segmental glomerulosclerosis. Pediatr Nephrol, 2007, vol. 22, no. 2, pp. 215-221.
- Fakhouri F., Bocquet N., Taupin P. et al. Steroid-sensitive nephrotic syndrome: from childhood to adulthood. Am J Kidney Dis., 2003, vol. 41, no. 3, pp. 550–557.
- Morozov S.L., Dlin V.V., Sukhorukov V.S., Voronkova A.S. Molecular nephropathology: new possibilities for the diagnosis of kidney disease. Rossiyskiy vestnik perinatologii i pediatrii, 2017, vol. 62, no. 3, pp. 32-36 (in Russ.).
- Morozov S.L., Dlin V.V., Sadykov A.R., Voronkova A.S., Sukhorukov V.S. Mechanisms of resistance to immunosuppressive therapy in patients with nephrotic syndrome. Rossiyskiy vestnik perinatologii i pediatrii, 2017, vol. 62, no. 4, pp. 19-24 (in Russ.).
- Miura M., Satoh S., Inoue K. et al. Influence of CYP3A5, ABCB1 and NR1I2 polymorphisms on prednisolone pharmacokinetics in renal transplant recipients. Steroids, 2008, 73, pp. 1052–1059.
- Ruochen C., Aihua Z. Mechanisms of Glucocorticoid Resistance in Idiopathic Nephrotic Syndrome. Kidney Blood Press Res., 2013, vol. 37, pp. 360-378.
- Llaudu I., Colom H., Gimynez-Bonafy P., et al. Do drug transporter (ABCB1) SNPs and P-glycoprotein function influence cyclosporine and macrolides exposure in renal transplant patients? Results of the pharmacogenomic substudy within the symphony study. Transpl Int., 2013, vol. 26, no. 2, pp. 177-186.
- Doaa Mohammed Youssef, Rabab Mohammed Elbehidy, Hosam Salah Abdelhalim, Ghada Elsyde Amr. Soluble Interleukine-2 Recptor and MDR1 Gene Expression Levels as Inflammatory Biomarkers for Prediction of Steroid Response in Children With Nephrotic Syndrome. Iranian Journal of Kidney Diseases, 2011, vol. 5, no. 3, pp. 154-176.
- Li Y., Hu X., Cai B., et al. Meta-analysis of the effect of MDR1 C3435 polymorphism on tacrolimus pharmacokinetics in renal transplant recipients. Transpl Immunol, 2012, no. 27, pp. 12-18.
- Crettol S., Venetz J.P., Fontana M. et al. Influence of ABCB1 genetic polymorphisms on cyclosporine intracellular concentration in transplant recipients. Pharmacogenet Genomics, 2008, no. 18, pp. 307-315.
- Capron A., Mourad M., De Meyer M. et al. CYP3A5 and ABCB1 polymorphisms influence tacrolimus concentrations in peripheral blood mononuclear cells after renal transplantation. Pharmacogenomics, 2010, no.11, pp.703-714.
- Wilkinson G.R. Drug metabolism and variability among patients in drug response. N Engl J Med, 2005, vol. 352, no. 21, pp. 2211-2221.
- Timm R., Kaiser R., Lotsch J. et al. Association of cyclophosphamide pharmacokinetics to polymorphic cytochrome. J. Pharmacogenomics, 2005, no. 5, pp. 365-373.
- Lunde I., Bremer S., Midtvedt K. et al. The influence of CYP3A, PPARA, and POR genetic variants on the pharmacokinetics of tacrolimus and cyclosporine in renal transplant recipients. Eur J Clin Pharmacol., 2014, no. 70, pp. 685–693.
- Julia M.B., Christine E.S., Raman V. Pharm GKB summary: cyclosporine and tacrolimus pathways. Pharmacogenet Genomics, 2013, vol. 23, no. 10, pp. 563-585.
- Kim R.B. Drugs as P-glycoprotein substrates, inhibitors, and inducers. Drug Metab Rev., 2002, vol. 34, no. 1-2, pp. 47-54.
- Jacobson P.A., Schladt D., Oetting W.S. et al. Genetic determinants of mycophenolate-related anemia and leukopenia after transplantation. Transplantation, 2011, no. 91, pp. 309–316.